CHCWM – Cancer & Hematology Centers of West Michigan

IK-175-001 (Ikena)

IK-175-001  (Ikena)

Description:  A Phase 1, Open-Label, Dose-Escalation and Expansion Study of IK-175, an Oral Aryl Hydrocarbon Receptor (AHR) Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

Mechanism of ActionIK175 (Aryl Hydrocarbon Receptor – AHR- blocker) – AHR mediates immune suppression in the tumor microenvironment. 

Target Patient Population:  Urothelial cancer

Study Design:  Study Drug is given orally daily